Exelixis | EXEL - Equity Capital And Reserves



Exelixis reported $2.03B in Equity Capital and Reserves for its fiscal quarter ending in July of 2025.


Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 822.38M 57.14M Jun/2025
Agios Pharmaceuticals USD 1.37B 96.97M Jun/2025
Amgen USD 7.43B 1.22B Jun/2025
AstraZeneca USD 44.72B 3.68B Jun/2025
Bayer EUR 30.5B 2.08B Jun/2025
BioMarin Pharmaceutical USD 6.03B 233.65M Jun/2025
Bristol-Myers Squibb USD 17.49B 100M Jun/2025
Cytokinetics USD -737440000 471.03M Jun/2025
Eisai JPY 828.51B 12.91B Jun/2025
Eli Lilly USD 18.27B 2.43B Jun/2025
Exelixis USD 2.03B 97.49M Jul/2025
Genmab DKK 5.3B 6M Jun/2025
Glaxosmithkline GBP 14.35B 683M Jun/2025
Incyte USD 4.17B 503.34M Jun/2025
Ionis Pharmaceuticals USD 631.72M 156M Jun/2025
MacroGenics USD 46.62M 69.44M Jun/2025
Merck USD 49.06B 725M Jun/2025
Moderna USD 9.4B 667M Jun/2025
Neurocrine Biosciences USD 2.69B 158.6M Jun/2025
Novartis USD 42.05B 3.6B Jun/2025
Pfizer USD 88.7B 1.64B Jun/2025
Sanofi 70.28B 7.58B Jun/2025
Takeda JPY 6.87T 69.82B Jun/2025
Ultragenyx Pharmaceutical USD 151.29M 7.04M Jun/2025
Xencor USD 620.35M 19.52M Jun/2025